Cancer Vaccines: Translation from Mice to Human Clinical Trials

Overview

Journal Curr Opin Immunol

Publisher Elsevier

Specialty Allergy & Immunology

Date 2018 Mar 20

PMID 29554495

Citations 26

Authors

Hoyoung Maeng

Masaki Terabe

Jay A Berzofsky

Affiliations

Soon will be listed here.

Abstract

Therapeutic cancer vaccines have been a long-sought approach to harness the exquisite specificity of the immune system to treat cancer, but until recently have not had much success as single agents in clinical trials. However, new understanding of the immunoregulatory mechanisms exploited by cancers has allowed the development of approaches to potentiate the effect of vaccines by removing the brakes while the vaccines step on the accelerator. Thus, vaccines that had induced a strong T cell response but no clinical therapeutic effect may now reach their full potential. Here, we review a number of promising approaches to cancer vaccines developed initially in mouse models and their translation into clinical trials, along with combinations of vaccines with other therapies that might allow cancer vaccines to finally achieve clinical efficacy against many types of cancer.

Citing Articles

Tumor targeting peptide TMTP1 modified Antigen capture Nano-vaccine combined with chemotherapy and PD-L1 blockade effectively inhibits growth of ovarian cancer.

Zhou Y, Wei R, Wang L, Li J, Wang W, Jiang G J Nanobiotechnology. 2024; 22(1):483.

PMID: 39138475 PMC: 11320875. DOI: 10.1186/s12951-024-02744-6.

Second-generation checkpoint inhibitors and Treg depletion synergize with a mouse cancer vaccine in accordance with tumor microenvironment characterization.

Becker W, Olkhanud P, Seishima N, Moreno P, Goldfarbmuren K, Maeng H J Immunother Cancer. 2024; 12(7).

PMID: 38955422 PMC: 11218019. DOI: 10.1136/jitc-2024-008970.

Next-Generation Adjuvants: Applying Engineering Methods to Create and Evaluate Novel Immunological Responses.

Kim J, Rosenberger M, Rutledge N, Esser-Kahn A Pharmaceutics. 2023; 15(6).

PMID: 37376133 PMC: 10300703. DOI: 10.3390/pharmaceutics15061687.

Sustained release of tumor cell lysate and CpG from an injectable, cytotoxic hydrogel for melanoma immunotherapy.

Yang K, Zhou Y, Huang B, Zhao G, Geng Y, Wan C Nanoscale Adv. 2023; 5(7):2071-2084.

PMID: 36998647 PMC: 10044724. DOI: 10.1039/d2na00911k.

Ionic Liquid-Based Transcutaneous Peptide Antitumor Vaccine: Therapeutic Effect in a Mouse Tumor Model.

Shimizu T, Matsuzaki T, Fukuda S, Yoshioka C, Shimazaki Y, Takese S AAPS J. 2023; 25(2):27.

PMID: 36805860 DOI: 10.1208/s12248-023-00790-w.

References

Abrams S, HAND P, Tsang K, Schlom J . Mutant ras epitopes as targets for cancer vaccines. Semin Oncol. 1996; 23(1):118-34. View

Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

Vetizou M, Pitt J, Daillere R, Lepage P, Waldschmitt N, Flament C . Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015; 350(6264):1079-84. PMC: 4721659. DOI: 10.1126/science.aad1329. View

Gibney G, Kudchadkar R, DeConti R, Thebeau M, Czupryn M, Tetteh L . Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res. 2014; 21(4):712-20. PMC: 4620684. DOI: 10.1158/1078-0432.CCR-14-2468. View

Freedland S, Humphreys E, Mangold L, Eisenberger M, Dorey F, Walsh P . Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005; 294(4):433-9. DOI: 10.1001/jama.294.4.433. View

Yee C, Thompson J, Byrd D, Riddell S, Roche P, Celis E . Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A. 2002; 99(25):16168-73. PMC: 138583. DOI: 10.1073/pnas.242600099. View

Kimura T, McKolanis J, Dzubinski L, Islam K, Potter D, Salazar A . MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila). 2012; 6(1):18-26. PMC: 3536916. DOI: 10.1158/1940-6207.CAPR-12-0275. View

Janssen E, Droin N, Lemmens E, Pinkoski M, Bensinger S, Ehst B . CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature. 2005; 434(7029):88-93. DOI: 10.1038/nature03337. View

Oh S, Hodge J, Ahlers J, Burke D, Schlom J, Berzofsky J . Selective induction of high avidity CTL by altering the balance of signals from APC. J Immunol. 2003; 170(5):2523-30. DOI: 10.4049/jimmunol.170.5.2523. View

10.

Fox B, Schendel D, Butterfield L, Aamdal S, Allison J, Ascierto P . Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011; 9:214. PMC: 3338100. DOI: 10.1186/1479-5876-9-214. View

11.

Terabe M, Matsui S, Park J, Mamura M, Noben-Trauth N, Donaldson D . Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med. 2003; 198(11):1741-52. PMC: 2194133. DOI: 10.1084/jem.20022227. View

12.

Hodge J, Chakraborty M, Kudo-Saito C, Garnett C, Schlom J . Multiple costimulatory modalities enhance CTL avidity. J Immunol. 2005; 174(10):5994-6004. PMC: 1924685. DOI: 10.4049/jimmunol.174.10.5994. View

13.

Freedman A, Neelapu S, Nichols C, Robertson M, Djulbegovic B, Winter J . Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol. 2009; 27(18):3036-43. PMC: 3646306. DOI: 10.1200/JCO.2008.19.8903. View

14.

Hui E, Cheung J, Zhu J, Su X, Taylor M, Wallweber H . T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017; 355(6332):1428-1433. PMC: 6286077. DOI: 10.1126/science.aaf1292. View

15.

Tran E, Robbins P, Lu Y, Prickett T, Gartner J, Jia L . T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med. 2016; 375(23):2255-2262. PMC: 5178827. DOI: 10.1056/NEJMoa1609279. View

16.

Janssen E, Lemmens E, Wolfe T, Christen U, von Herrath M, Schoenberger S . CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003; 421(6925):852-6. DOI: 10.1038/nature01441. View

17.

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

18.

Park J, Terabe M, Steel J, Forni G, Sakai Y, Morris J . Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine. Cancer Res. 2008; 68(6):1979-87. DOI: 10.1158/0008-5472.CAN-07-5688. View

19.

Le D, Lutz E, Uram J, Sugar E, Onners B, Solt S . Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother. 2013; 36(7):382-9. PMC: 3779664. DOI: 10.1097/CJI.0b013e31829fb7a2. View

20.

Spranger S, Bao R, Gajewski T . Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015; 523(7559):231-5. DOI: 10.1038/nature14404. View